Cargando…
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We soug...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685714/ https://www.ncbi.nlm.nih.gov/pubmed/29163793 http://dx.doi.org/10.18632/oncotarget.21163 |
_version_ | 1783278671476293632 |
---|---|
author | Hovelson, Daniel H. Liu, Chia-Jen Wang, Yugang Kang, Qing Henderson, James Gursky, Amy Brockman, Scott Ramnath, Nithya Krauss, John C. Talpaz, Moshe Kandarpa, Malathi Chugh, Rashmi Tuck, Missy Herman, Kirk Grasso, Catherine S. Quist, Michael J. Feng, Felix Y. Haakenson, Christine Langmore, John Kamberov, Emmanuel Tesmer, Tim Husain, Hatim Lonigro, Robert J. Robinson, Dan Smith, David C. Alva, Ajjai S. Hussain, Maha H. Chinnaiyan, Arul M. Tewari, Muneesh Mills, Ryan E. Morgan, Todd M. Tomlins, Scott A. |
author_facet | Hovelson, Daniel H. Liu, Chia-Jen Wang, Yugang Kang, Qing Henderson, James Gursky, Amy Brockman, Scott Ramnath, Nithya Krauss, John C. Talpaz, Moshe Kandarpa, Malathi Chugh, Rashmi Tuck, Missy Herman, Kirk Grasso, Catherine S. Quist, Michael J. Feng, Felix Y. Haakenson, Christine Langmore, John Kamberov, Emmanuel Tesmer, Tim Husain, Hatim Lonigro, Robert J. Robinson, Dan Smith, David C. Alva, Ajjai S. Hussain, Maha H. Chinnaiyan, Arul M. Tewari, Muneesh Mills, Ryan E. Morgan, Todd M. Tomlins, Scott A. |
author_sort | Hovelson, Daniel H. |
collection | PubMed |
description | Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization. |
format | Online Article Text |
id | pubmed-5685714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56857142017-11-21 Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy Hovelson, Daniel H. Liu, Chia-Jen Wang, Yugang Kang, Qing Henderson, James Gursky, Amy Brockman, Scott Ramnath, Nithya Krauss, John C. Talpaz, Moshe Kandarpa, Malathi Chugh, Rashmi Tuck, Missy Herman, Kirk Grasso, Catherine S. Quist, Michael J. Feng, Felix Y. Haakenson, Christine Langmore, John Kamberov, Emmanuel Tesmer, Tim Husain, Hatim Lonigro, Robert J. Robinson, Dan Smith, David C. Alva, Ajjai S. Hussain, Maha H. Chinnaiyan, Arul M. Tewari, Muneesh Mills, Ryan E. Morgan, Todd M. Tomlins, Scott A. Oncotarget Research Paper Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization. Impact Journals LLC 2017-09-22 /pmc/articles/PMC5685714/ /pubmed/29163793 http://dx.doi.org/10.18632/oncotarget.21163 Text en Copyright: © 2017 Hovelson et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Hovelson, Daniel H. Liu, Chia-Jen Wang, Yugang Kang, Qing Henderson, James Gursky, Amy Brockman, Scott Ramnath, Nithya Krauss, John C. Talpaz, Moshe Kandarpa, Malathi Chugh, Rashmi Tuck, Missy Herman, Kirk Grasso, Catherine S. Quist, Michael J. Feng, Felix Y. Haakenson, Christine Langmore, John Kamberov, Emmanuel Tesmer, Tim Husain, Hatim Lonigro, Robert J. Robinson, Dan Smith, David C. Alva, Ajjai S. Hussain, Maha H. Chinnaiyan, Arul M. Tewari, Muneesh Mills, Ryan E. Morgan, Todd M. Tomlins, Scott A. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title_full | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title_fullStr | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title_full_unstemmed | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title_short | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy |
title_sort | rapid, ultra low coverage copy number profiling of cell-free dna as a precision oncology screening strategy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685714/ https://www.ncbi.nlm.nih.gov/pubmed/29163793 http://dx.doi.org/10.18632/oncotarget.21163 |
work_keys_str_mv | AT hovelsondanielh rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT liuchiajen rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT wangyugang rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT kangqing rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT hendersonjames rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT gurskyamy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT brockmanscott rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT ramnathnithya rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT kraussjohnc rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT talpazmoshe rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT kandarpamalathi rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT chughrashmi rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT tuckmissy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT hermankirk rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT grassocatherines rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT quistmichaelj rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT fengfelixy rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT haakensonchristine rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT langmorejohn rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT kamberovemmanuel rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT tesmertim rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT husainhatim rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT lonigrorobertj rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT robinsondan rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT smithdavidc rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT alvaajjais rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT hussainmahah rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT chinnaiyanarulm rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT tewarimuneesh rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT millsryane rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT morgantoddm rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy AT tomlinsscotta rapidultralowcoveragecopynumberprofilingofcellfreednaasaprecisiononcologyscreeningstrategy |